Septa Pharmaceuticals Acquires CeeNU (Lomustine) from Bristol Myers Squibb Canada, Strengthening Oncology Portfolio
Key Insights
Septa Pharmaceuticals Inc. (search) completed the acquisition of CeeNU® (lomustine) from Bristol Myers Squibb (search) Canada as of June 29, 2026.
CeeNU is an established alkylating agent used primarily in treating specific brain tumors (search) and Hodgkin's lymphoma (search).
The acquisition reinforces Septa's specialty oncology portfolio and its commitment to ensuring uninterrupted patient access across Canada.
Septa Pharmaceuticals Inc. (search), a rapidly growing leader in the Canadian healthcare sector, has successfully acquired CeeNU® (lomustine) from Bristol Myers Squibb (search) Canada, effective June 29, 2026. The strategic acquisition, announced on July 15, 2026, represents a significant milestone in Septa's ongoing expansion and underscores the company's dedication to strengthening its specialty oncology pharmaceutical portfolio.
CeeNU® (lomustine) is an established and highly valued alkylating agent utilized primarily in the treatment of specific types of brain tumors (search) and Hodgkin's lymphoma (search). By integrating this essential chemotherapy medication into its product lineup, Septa is reinforcing its footprint in the critical care and oncology space.
Commitment to Uninterrupted Patient Access
Septa emphasized that CeeNU® represents an important therapeutic option for many individuals battling severe health conditions. The company is deeply committed to ensuring continuous, uninterrupted patient access to this vital medication across Canada. Recognizing the critical need for a robust and stable supply of essential medicines in today's complex healthcare landscape, Septa is prioritizing the long-term availability of CeeNU®.
"As we integrate CeeNU® (lomustine) into our growing portfolio, our primary focus remains firmly on the patients and the medical professionals who treat them," said Devinder K., President & CEO of Septa Pharmaceuticals Inc. (search) "We are working collaboratively and closely with all relevant stakeholders, including regulatory bodies and supply chain partners, to ensure a seamless transition. This acquisition is a profound testament to our core mission of providing high-quality, reliable pharmaceutical products that tangibly improve health outcomes both across the country and globally."
Strategic Growth and Future Partnerships
As Septa rapidly broadens its diverse product portfolio and expands its geographic territories, the company is actively seeking new strategic partnerships and licensing opportunities. The company has signaled its openness to collaborations with pharmaceutical companies to out-license, in-license, launch, and commercialize high-impact therapies globally, aiming to drive mutual growth and ensure vital medicines reach global markets.